Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Melanin-Concentrating Hormone Receptor 1 (MCHR1)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101710


Historical Background

MCHR1 is a receptor for melanin-concentrating hormone (MCH). MCH was originally discovered from salmon pituitary as a 17-amino acid cyclic peptide (Kawauchi et al. 1983); in teleost fish, MCH causes the aggregation of melanosomes in the scales, which lightens skin color. The mammalian form of MCH is highly homologous to that of the teleost, but its expression is detected at high levels in the lateral hypothalamus, which is classically a feeding center (Bittencourt et al. 1992). Based on physiological and genetic experiments, MCH is strongly implicated in the regulation of feeding behavior and energy metabolism (Shimada et al. 1998).

Initial efforts to identify the receptor for MCH were based on binding assays by using radiolabeled MCH. MCH binding was detected in mouse melanoma cells in vitro and in rat brain, as well as in some peripheral tissues. However, the identity of MCH receptor was unknown until it was revealed to be an orphan G-protein-coupled receptor (GPCR), SLC-1. SLC-1 was cloned from rat DNA by PCR amplification and characterized as a GPCR with 40% amino acid identity in the transmembrane (TM) regions of the five known human somatostatin receptors. SLC-1 gene is intron-less in its open reading frame, encodes a receptor of 353 amino acids in the rat, and maps to chromosome 22, q13.3 in humans. The MCH receptor was discovered by two approaches. The first used an orphan receptor strategy (Civelli 2012). In principle, an orphan GPCR is transfected into cell lines, which are then exposed to biological extracts to provoke receptor-induced changes in intracellular signaling, such as second-messenger activation. An active component can be isolated by monitoring changes in messenger systems such as calcium mobilization. Three groups used rat whole brain extract as material to identify the endogenous agonist for SLC-1 by measuring three second-messenger responses: (1) calcium mobilization in CHO cells transiently transfected with a chimeric Gα protein (Gαq/i3) and rat SLC-1, (2) cyclic AMP (cAMP) inhibition assays in CHO cells stably expressing human SLC-1, and (3) G-protein-coupled inwardly-rectifying potassium channel (GIRK)-mediated current in Xenopus oocytes expressing rat SLC-1 and GIRK. These groups independently reached to the same conclusion that MCH is the only ligand from rat brain extract to activate either rat or human SLC-1 receptor. Two other groups used the reverse pharmacology approach to identify a ligand for SLC-1 receptor. A compound library containing more than 500 known bioactive substances was used to search for any known ligand that has activity at the human SLC-1 receptor. Among those, MCH was the only compound to activate the SLC-1 receptor with nanomolar affinity. Finally, the conclusion from all five groups was that SLC-1 is a receptor for MCH (Chambers et al. 1999; Saito et al. 1999). A second MCH receptor subtype, designated MCHR2, was identified by six independent groups using human genomic sequence searches (Mori et al. 2001). It shares 31.5% amino acid identity with MCHR1 and shows high-affinity MCH binding. In contrast to MCHR1, MCHR2 couples to Gαq but not to Gαi/o proteins. The human MCHR2 gene is mapped to the long arm of chromosome 6 at band 6q16.2–16.3, a region reported to be associated with cytogenetic abnormalities of obese patients. MCHR2 is a pseudogene in rodent species, but is functional in dogs, ferrets, rhesus monkeys, and humans (Tan et al. 2002). Thus, MCH acts solely through the MCHR1 in rodents.

MCHR1 is not found in Ciona intestinalis, Caenorhabditis elegans, or Drosophila melanogaster (Fredriksson and Schiöth 2005). In fish, three MCH receptor sequences from zebrafish have been identified in whole-genome shotgun datasets, while two receptors were cloned from barfin flounder and goldfish. In amphibians, the full-length cDNA structures of four MCH receptors (MCHR1a, MCHR1b, MCHR2a, and MCHR2b) were determined and functionally characterized from the diploid species Xenopus tropicalis. Barfin flounder, goldfish, and Xenopus tropicalis have clear MCHR1 and MCHR2 orthologues. Phylogenetic analyses of these receptors have suggested that an initial duplication of the MCH receptor occurred early in evolution, giving rise to MCHR1 and MCHR2 (Fig. 1) (Kobayashi et al. 2015). This information will help to elucidate the evolution of MCH receptor among whole vertebrates.
Melanin-Concentrating Hormone Receptor 1 (MCHR1), Fig. 1

Phylogenetic tree of the MCH receptors, constructed by the neighbor-joining method. MCHR1 (left side) and MCHR2 (right side) formed separate clusters. Each cluster contains mammalian-type (red) and teleostean-type (blue, including Xenopus tropicalis) MCHR subtypes. The phylogenetic relationship of the fish, amphibian, and mammalian MCHR proteins suggests that an ancestral MCHR underwent the first gene duplication during the evolution into fish, resulting in MCHR1 and MCHR2. Secondary gene duplication events are believed to have occurred during the evolution from fish to amphibians, resulting in MCHR1a and MCHR1b subtypes. Subsequently, X-MCHR1b was lost, whereas X-MCHR1a was passed on from amphibians to mammals. Considering that a single MCHR (MCHR1) is present in rodents, the MCHR2 ortholog appears to have been lost after the separation of rodents from other mammals. The scale bar indicates the distance in terms of the number (0.2) of amino acid substitutions per site

Physiological Functions in the Central Nervous System

While MCHR1 is present in several peripheral tissues, such as adipose and islets of Langerhans, MCHR1 mRNA is detected at very high levels in the brain (Hervieu et al. 2000; Saito et al. 2001). There were clear mRNA signals in the olfactory nucleus, olfactory tubercle, and piriform cortex. Strong labeling is detected in several limbic structures, including the hippocampal formation, septum, and amygdala. Distinct MCHR1 signals have also been detected in the locus coeruleus, the major noradrenergic nucleus. Furthermore, the nucleus accumbens shell, which plays a role in the regulation of motivation and reward, contains very high levels of MCHR1 mRNA. Moderate mRNA expression is found in various hypothalamic regions including the arcuate nucleus, ventromedial hypothalamic nucleus, and paraventricular nucleus that are involved in feeding and energy homeostasis. Autoradiographic analysis using a MCHR1-specific radioligand also showed intense binding to the rat nucleus accumbens, caudate-putamen, and piriform cortex (Able et al. 2009). This diffuse localization indicates the diversity of physiological functions of the MCH-MCHR1 system.

Various rodent genetic models have implicated the MCH-MCHR1 system as an important factor in the control of feeding and energy metabolism (MacNeil 2013). For example, mice and rats lacking prepro-MCH are hypophagic and lean, with increased resting energy expenditure. Furthermore, the selective loss of MCH neurons results in late-onset leanness of body weight in mice (Alon and Friedman 2006), and the deletion of the MCHR1 gene in mice produces increased locomotor activity and metabolic rate, such that the mice display mild overeating but remain lean with lower body fat (Chen et al. 2002; Marsh et al. 2002). Such hyperactivity could be due to an increase in dopaminergic sensitivity in the nucleus accumbens. A series of in vivo pharmacological studies used MCHR1-selective antagonists provided further evidence for the role of MCHR1 in energy homeostasis, while several non-peptide MCHR1 antagonists have shown efficacy in a variety of rodent models for acute food intake (Takekawa et al. 2002; Luthin 2007). A number of MCHR1 antagonists caused sustained and dose-dependent efficacy in chronic models of obesity. However, there are few reports confirming the specificity of these MCHR1 antagonists in MCHR1 knockout mice, and further research using MCHR1-specific models is required to fully understand the efficacy of MCHR1 antagonists in food intake systems.

Some MCHR1 antagonists exhibit anxiolytic- and antidepressant-like behavior when tested in a variety of preclinical behavioral models such as the forced-swim test, elevated plus-maze, stress-induced hyperthermia paradigm, and social interaction test (Borowsky et al. 2002; Antal-Zimanyi and Khawaja 2009). Consistent with this, MCHR1 knockout mice display reduced anxiety responses. Recently, a central action of the MCHR1 has also been revealed a role in arousal and sleep. Both optogenetic and pharmacological studies suggested that MCHR1-mediated signaling promotes paradoxical (REM) sleep. By contrast, MCHR1-deficient mice exhibit a hypersomnia-like phenotype, characterized by higher amounts of REM sleep during the active dark phase, especially after sleep deprivation. These conflicting reports could highlight genetic differences in sleep mechanisms, or alternatively that MCHR1 may mediate auto-inhibition of MCH neurons localized in the lateral hypothalamus (Richter et al. 2014). Such loss of this inhibitory feedback loop in MCHR1 knockout mice would enable MCH neurons to release its co-transmitter, GABA, which could initiate REM sleep episodes and prolong their duration.

Regulation of MCHR1 Activity

When transfected into CHO or HEK293 cells, MCHR1 can elicit calcium mobilization, inhibit forskolin-induced cAMP generation, and stimulate extracellular signal-regulated kinase (ERK) phosphorylation via Gαi/o- and Gαq-mediated signaling (Chambers et al. 1999; Saito et al. 1999; Hawes et al. 2000). Figure 2 shows a representative model of MCHR1-induced intracellular signaling pathways. Pertussis toxin (PTX) – which inhibits Gαi/o proteins – partially inhibits MCH-stimulated inositol phosphate production and calcium mobilization, suggesting that these signals are transduced by both Gαi/o- and Gαq-mediated pathways. MCH-induced ERK phosphorylation is also stimulated by Gαi, Gαo, and Gαq proteins but via different mechanisms (Hawes et al. 2000). Protein kinase C (PKC) activity is required for Gαq- and Gαo-dependent ERK phosphorylation. However, it appears to be the βγ-subunit rather than the Gα-subunit that mediates the majority of Gαi-mediated MCH-stimulated ERK phosphorylation. Differential activation of these various intracellular signaling pathways may underlie the diversity of in vivo physiological processes regulated by MCH.
Melanin-Concentrating Hormone Receptor 1 (MCHR1), Fig. 2

MCH-induced signaling pathways in CHO or HEK293 cells transfected with mammalian MCHR1. MCHR1 couples to multiple G-proteins (Gαi, Gαo, and Gαq). MCHR1 activation results in increased calcium mobilization, inhibition of cAMP accumulation, and stimulation of ERK phosphorylation

Extensive mutagenesis analyses have demonstrated several amino acid residues of MCHR1 that are important for receptor function. The various sites thought to be responsible for MCHR1 function are summarized in Fig. 3. The DRY motif is highly conserved between rhodopsin family members and is involved in maintaining the receptor in its ground state. Alanine substitution of either Asp140 (D140A) or Tyr142 (Y142A) produced loss-of-function phenotypes without changing ligand-binding capacity. Various conserved proline residues in the second, fourth, fifth, sixth, and seventh transmembrane domains (P97, P177, P220, P271, and P308, respectively) are important for mature glycosylation. Notably, cell surface expression of a P308 mutant was dramatically reduced, resulting in impairment of calcium mobilization.
Melanin-Concentrating Hormone Receptor 1 (MCHR1), Fig. 3

Structure-activity relationship of mammalian MCHR1. (a) Amino acid residues involved in MCHR1 function. The highly conserved DRY motif is essential for receptor conformation and G-protein coupling. Other highly conserved Pro residues (white circles) are important for mature glycosylation and intracellular signaling. N13, N16, and N23 (red circles) are N-glycosylation sites. D123 (blue circle) plays a critical role in ligand binding. R155, R319, and K320 (green circles) are key residues for receptor signaling via Gαi/o- and Gαq-mediated pathways. R253 and R256 (orange circles) are structurally important residues for functional interaction with RGS8. T255 (brown circle) is essential for receptor folding and correct trafficking to the cell surface. The distal part of the C-terminal tail (light blue square) is necessary for receptor internalization. In addition, the use of ciliated hRPE1 cells has revealed A240 and A242 (purple circles) as being ciliary targeting residues that have no role in ciliogenesis. (b) Amino acid residues that are selectively responsible for Gαi/o or Gαq protein activation by rat MCHR1. Two MCHR1 mutants, i2_6sub and i3_6sub, which contain multiple substituted residues (S150R/S151F/T152N/K153H/K156T/S158C and Y228F/V229F/R234N/A242L/S243P/T257M, respectively) significantly reduce Gαi/o-selective signaling, whereas F318K substitution in the NPxxY(x)5,6F motif produces a mutant that selectively signals via the Gαq-mediated pathway. Colored circles and rectangles denote amino acid residues that are important for mammalian MCHR1 function. TM transmembrane domain

The extracellular N-terminal domain of rat MCHR1 has three N-linked glycosylation sites (Asn13, Asn16, and Asn23). These residues, particularly Asn23, are necessary for receptor expression at the cell surface, ligand binding, and signal transduction. Molecular modeling of the MCH-MCHR1 identified that Asp123 in the third transmembrane domain plays a crucial role in ligand binding and receptor activation (Macdonald et al. 2000). Indeed, substitution of Asp123 resulted in a loss of detectable MCH binding and of MCH-stimulated calcium mobilization, despite having no effect on cell surface expression. In the second intracellular loop, mutation of Arg155 (R155Q) led to a drastic loss of Gαi/o- and Gαq-mediated signaling, although no significant change was observed in ligand-binding activity (Saito et al. 2005). A T255A mutant, which substitutes alanine for a threonine residue located at the junction of the third intracellular loop and the sixth transmembrane domain, was largely retained in the endoplasmic reticulum causing a dramatic loss of cell surface expression (Fan et al. 2005). In helix 8 – a short cytoplasmic amphiphilic helical domain in the proximal C-terminal tail – two dibasic amino acids (Arg319 and Lys320) are essential for Gαi/o- and Gαq-mediated signaling (Tetsuka et al. 2004), while the distal part of the C-terminal tail is necessary for receptor internalization. Indeed, triple substitution of T317A/S325A/T342A partially prevents MCH-induced receptor internalization through PKC and β-arrestin 2-dependent processes without affecting signal transduction.

Mammalian MCHR1 couples to both Gαi/o and Gαq, whereas goldfish MCHR1 exclusively couples to Gαq. By analyzing sequence alignments between those two MCHR1 variants, two mutants with multiple substitutions in either the second intracellular loop or in the third intracellular loop and fifth transmembrane domain, respectively (Fig. 3b), were found to exhibit reduced Gαi/o activity without altering Gαq-mediated signaling (Hamamoto et al. 2015). Thus, two regions (S150/S151/T152/K153/K156/S158 and Y228/V229/R234/A242/S243/T257) appear to independently affect Gαi/o-protein preference. Meanwhile, point mutation of F318K, located in the conserved NPxxY(x)5,6F motif, produces a receptor that efficiently and selectively signal via Gαq, with no concomitant Gαi/o-mediated signaling (Hamamoto et al. 2012).

The signaling properties of MCHR1 are depending on the cellular context. Such fine-tuning of receptor function can be attributed to receptor-selective partners. Regulator of G-protein signaling (RGS) proteins are direct modulators of G-protein activity, binding to the activated form of Gα and enhancing its GTPase activity, which inhibits GPCR-mediated signaling. Among 30 different RGS proteins, RGS8 significantly suppresses MCHR1-induced calcium mobilization (Miyamoto-Matsubara et al. 2008). Arg253 and Arg256, which are located at the distal end of the third intracellular loop, are structurally essential residues for direct interaction with the N-terminus of RGS8 (Fig. 3a). Moreover, the actin- and intermediate filament-binding protein, periplakin, and the neurite outgrowth-related factor, neurochondrin, both interact with the proximal C-terminus of MCHR1 (but not with the third intracellular loop), resulting in reduced MCH-mediated signaling (Murdoch et al. 2005). Interactions of MCHR1 with neurochondrin and periplakin were competitive, indicating that these proteins bind to overlapping regions of MCHR1.

MCHR1 Localized in Primary Cilia

Primary cilia are specialized microtubule-based organelles that project from the cell surface in most vertebrate cells. These cilia convert extracellular signals into a cellular response, thereby functioning as sensory antennae. The physiological importance of neuronal cilia is highlighted by rare human genetic diseases involving primary cilia (ciliopathies), such as autosomal recessive Bardet-Biedl syndrome (BBS) and Alstrom syndrome, in which patients exhibit truncal obesity, renal dysfunction, and behavioral dysfunction (Hildebrandt et al. 2011). Primary cilia also serve as signaling hubs through selective interactions with ion channels and conventional (nonolfactory) GPCRs (Schou et al. 2015). Among the many GPCRs, only a small subset (that includes MCHR1) is highly enriched in neuronal cilia. MCHR1 fails to accumulate in the ciliary membrane in distinct brain regions including hippocampus and nucleus accumbens in both BBS2 and BBS4 knockout mice (Berbari et al. 2008). Altered MCHR1 signaling in the ciliary membrane lacking this receptor could lead to irregular activation or downregulation of signaling in these mutant mice. Because BBS is associated with hyperphagia-induced obesity, specific signaling via ciliary MCHR1 may be functionally important in the regulation of feeding and energy homeostasis. Furthermore, a recent report describes that MCHR1-mediated signaling effectively induces shortening of the ciliary length via a Gαi/o-dependent Akt pathway in hRPE1 cells (Hamamoto et al. 2016). This may suggest that the MCH-MCHR1 axis can modulate the sensitivity of cells to external environments – including satiety signals – by controlling cilia length in a non-synaptic-dependent manner. Neuronal cilia were significantly shortened in the hypothalamus of diet-induced obese mice and ob/ob leptin-deficient obese mice and in the hippocampus and amygdala of BBS4 knockout mice. Further characterization of MCHR1 as a ciliary GPCR may reveal further evidence of a potential molecular mechanism link ciliary length control with obesity.


Considerable literature has accumulated to support the involvement of the hypothalamic neuropeptide, MCH, in the regulation of food intake. The identification of a specific receptor for MCH, found to be the previously identified orphan GPCR, SLC-1 (MCHR1), had an immediate impact, and the importance of the MCH-MCHR1 axis in feeding and energy expenditure in vivo was confirmed through the publication of extensive studies using MCHR1-selective antagonists and genetically engineered animals. MCHR1 mRNA is widely expressed in the brain, suggesting a role for the MCH-MCHR1 axis in diverse physiological functions and behavioral outcomes such as anxiety, stress, and sleep/wakefulness responses. When MCHR1 is transfected into mammalian cells, MCHR1 activates second messengers by coupling to Gαi/o and Gαq proteins. Using such heterologous expression systems, site-directed mutagenesis studies have been performed which have provided deep insight into the structure-function relationships of the MCHR1. These studies may aid the development of a novel antagonist or allosteric modulator of MCHR1 signaling, which could revolutionize our understanding of the physiological roles of the endogenous MCHR1.


  1. Able SL, Ivarsson M, Fish RL, Clarke TL, McCourt C, Duckworth JM, Napier C, Katugampola SD. Localisation of melanin-concentrating hormone receptor 1 in rat brain and evidence that sleep parameters are not altered despite high central receptor occupancy. Eur J Pharmacol. 2009;616:101–6.PubMedCrossRefGoogle Scholar
  2. Alon T, Friedman JM. Late-onset leanness in mice with targeted ablation of melanin concentrating hormone neurons. J Neurosci. 2006;26:389–97.PubMedCrossRefGoogle Scholar
  3. Antal-Zimanyi I, Khawaja X. The role of melanin-concentrating hormone in energy homeostasis and mood disorders. J Mol Neurosci. 2009;39:86–98.PubMedCrossRefGoogle Scholar
  4. Berbari NF, Johnson AD, Lewis JS, Askwith CC, Mykytyn K. Identification of ciliary localization sequences within the third intracellular loop of G protein-coupled receptors. Mol Biol Cell. 2008;19:1540–7.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol. 1992;319:218–45.PubMedCrossRefGoogle Scholar
  6. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002;8:825–30.PubMedCrossRefGoogle Scholar
  7. Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin J, Liu WS, Park J, Ellis JC, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Sarau HM. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. 1999;400:261–5.PubMedCrossRefGoogle Scholar
  8. Chen Y, Hu C, Hsu CK, Zhang Q, Bi C, Asnicar M, Hsiung HM, Fox N, Slieker LJ, Yang DD, Heiman ML, Shi Y. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology. 2002;143:2469–77.PubMedCrossRefGoogle Scholar
  9. Civelli O. Orphan GPCRs and neuromodulation. Neuron. 2012;76:12–21.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Fan J, Perry SJ, Gao Y, Schwarz DA, Maki RA. A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking. Mol Endocrinol. 2005;19:2579–90.PubMedCrossRefGoogle Scholar
  11. Fredriksson R, Schiöth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol. 2005;67:1414–25.PubMedCrossRefGoogle Scholar
  12. Hamamoto A, Horikawa M, Saho T, Saito Y. Mutation of Phe318 within the NPxxY(x)(5,6)F motif in melanin-concentrating hormone receptor 1 results in an efficient signaling activity. Front Endocrinol (Lausanne). 2012;26:147.Google Scholar
  13. Hamamoto A, Kobayashi Y, Saito Y. Identification of amino acids that are selectively involved in Gi/o activation by rat melanin-concentrating hormone receptor 1. Cell Signal. 2015;27:818–27.PubMedCrossRefGoogle Scholar
  14. Hamamoto A, Yamato S, Katoh Y, Nakayama K, Yoshimura K, Takeda S, Kobayashi Y, Saito Y. Modulation of primary cilia length by melanin-concentrating hormone receptor 1. Cell Signal. 2016;28:572–84.PubMedCrossRefGoogle Scholar
  15. Hawes BE, Kil E, Green B, O’Neill K, Fried S, Graziano MP. The melanin-concentrating hormone couples to multiple G proteins to activate diverse intracellular signaling pathways. Endocrinology. 2000;141:4524–32.PubMedCrossRefGoogle Scholar
  16. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, Leslie RA. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci. 2000;12:1194–216.PubMedCrossRefGoogle Scholar
  17. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. New Engl J Med. 2011;364:1533–43.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Kawauchi H, Kawazoe I, Tsubokaw M, Kishida M, Baker BL. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature. 1983;305:321–3.PubMedCrossRefGoogle Scholar
  19. Kobayashi Y, Hamamoto A, Hirayama T, Saito Y. Molecular cloning, expression, and signaling pathway of four melanin-concentrating hormone receptors from Xenopus tropicalis. Gen Comp Endocrinol. 2015;212:114–23.PubMedCrossRefGoogle Scholar
  20. Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci. 2007;81:423–40.PubMedCrossRefGoogle Scholar
  21. Macdonald D, Murgolo N, Zhang R, Durkin JP, Yao X, Strader CD, Graziano MP. Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation. Mol Pharmacol. 2000;58:217–25.PubMedCrossRefGoogle Scholar
  22. Macneil DJ. The role of melanin-concentrating hormone and its receptors in energy homeostasis. Front Endocrinol (Lausanne). 2013;4:49.Google Scholar
  23. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, Shen Z, Frazier EZ, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNeil DJ, Strack AM, MacIntyre DE, Van der Ploeg LH, Qian S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A. 2002;99:3240–5.Google Scholar
  24. Miyamoto-Matsubara M, Saitoh O, Maruyama K, Aizaki Y, Saito Y. Regulation of melanin-concentrating hormone receptor 1 signaling by RGS8 with the receptor third intracellular loop. Cell Signal. 2008;20:2084–94.PubMedCrossRefGoogle Scholar
  25. Mori M, Harada M, Terao Y, Sugo T, Watanabe T, Shimomura Y, Abe M, Shintani Y, Onda H, Nishimura O, Fujino M. Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor. Biochem Biophys Res Commun. 2001;283:1013–8.PubMedCrossRefGoogle Scholar
  26. Murdoch H, Feng GJ, Bachner D, Ormiston L, White JH, Richter D, Milligan G. Periplakin interferes with G protein activation by the melanin-concentrating hormone receptor-1 by binding to the proximal segment of the receptor C-terminal tail. J Biol Chem. 2005;280:8208–20.PubMedCrossRefGoogle Scholar
  27. Richter C, Woods IG, Schier AF. Neuropeptidergic control of sleep and wakefulness. Annu Rev Neurosci. 2014;37:503–31.PubMedCrossRefGoogle Scholar
  28. Saito Y, Nothacker HP, Wang Z, Lin S, Leslie FM, Civelli O. Molecular characterization of the melanin-concentrating-hormone receptor. Nature. 1999;400:265–9.PubMedCrossRefGoogle Scholar
  29. Saito Y, Cheng M, Leslie FM, Civelli O. Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol. 2001;435:26–40.PubMedCrossRefGoogle Scholar
  30. Saito Y, Tetsuka M, Saito S, Imai K, Yoshikawa A, Doi H, Maruyama K. Arginine residue 155 in the second intracellular loop plays a critical role in rat melanin-concentrating hormone receptor 1. Endocrinology. 2005;146:3452–62.PubMedCrossRefGoogle Scholar
  31. Schou KB, Pedersen LB, Christensen ST. Ins and outs of GPCR signaling in primary cilia. EMBO Rep. 2015;16:1099–113.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature. 1998;396:670–4.PubMedCrossRefGoogle Scholar
  33. Takekawa S, Asami A, Ishihara Y, Terauchi J, Kato K, Shimomura Y, Mori M, Murakoshi H, Kato K, Suzuki N, Nishimura O, Fujino M. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol. 2002;438:129–35.PubMedCrossRefGoogle Scholar
  34. Tan CP, Sano H, Iwaasa H, Pan J, Sailer AW, Hreniuk DL, Feighner SD, Palyha OC, Pong SS, Figueroa DJ, Austin CP, Jiang MM, Yu H, Ito J, Ito M, Ito M, Guan XM, MacNeil DJ, Kanatani A, Van der Ploeg LH, Howard AD. Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. Genomics. 2002;79:785–92.PubMedCrossRefGoogle Scholar
  35. Tetsuka M, Saito Y, Imai K, Doi H, Maruyama K. The basic residues in the membrane-proximal C-terminal tail of the rat melanin-concentrating hormone receptor 1 are required for receptor function. Endocrinology. 2004;145:3712–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Laboratory for Behavioral Neuroscience, Graduate School of Integrated Arts and SciencesHiroshima UniversityHiroshimaJapan
  2. 2.Molecular Genetics, Institute of Life ScienceKurume UniversityFukuokaJapan